Morningstar Fund Report  | 17/04/2025Print

Pictet-Biotech R USD

Performance History31/03/2025
Growth of 1,000 (GBP) Advanced Graph
Pictet-Biotech R USD
Fund-8.3-5.46.6-0.2-11.1
+/-Cat0.72.57.92.7-4.8
+/-B’mrk-8.6-7.8-0.76.4-7.7
 
Category: Sector Equity Biotechnology
Category Benchmark: Morningstar Gbl Biotechnolo...
Key Stats
NAV
16/04/2025		 USD 642.57
Day Change -2.90%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU0112497440
Fund Size (Mil)
15/04/2025		 USD 1113.28
Share Class Size (Mil)
15/04/2025		 USD 183.61
Max Initial Charge 3.00%
Ongoing Charge
07/02/2025		  2.70%
Investment Objective: Pictet-Biotech R USD
To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.
Returns
Trailing Returns (GBP)16/04/2025
YTD-19.48
3 Years Annualised-1.76
5 Years Annualised-2.68
10 Years Annualised-0.17
12 Month Yield 0.00
Management
Manager Name
Start Date
Tazio Storni
26/05/2016
Marco Minonne
01/06/2020
Click here to see others
Inception Date
27/06/2000

Category Benchmark
Fund BenchmarkMorningstar Benchmark
MSCI ACWI NR EURMorningstar Gbl Biotechnology NR USD
Portfolio Profile for  Pictet-Biotech R USD31/03/2025
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock98.050.0098.05
Bond0.170.000.17
Property0.000.000.00
Cash2.991.211.78
Other0.000.000.00
Top 5 Regions%
United States87.23
Asia - Emerging5.14
Eurozone3.88
Canada1.79
United Kingdom1.41
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Gilead Sciences IncHealthcareHealthcare6.13
Insmed IncHealthcareHealthcare5.29
argenx SE ADRHealthcareHealthcare5.04
Amgen IncHealthcareHealthcare4.50
Regeneron Pharmaceuticals IncHealthcareHealthcare3.80
Increase Decrease New since last portfolio
Pictet-Biotech R USD
Growth Of 1000 (GBP) 31/03/2025
Fund:  Pictet-Biotech R USD
Category:  Sector Equity Biotechnology
Category Index:  Morningstar Gbl Biotechnology NR USD
Growth of 1,000 GBP
Annual Returns (GBP)31/03/2025
 201820192020202120222023202431/03
Price Return-10.1924.9523.11-8.34-5.386.61-0.22-11.15
+/- Category-2.234.75-2.860.692.467.892.70-4.80
+/- Category Index-8.348.24-9.82-8.64-7.84-0.736.36-7.67
% Rank in Category7530336263185084
Trailing Returns (GBP)16/04/2025
   Total Returns   +/- Category   +/- Category Index
1 Day-2.90   -4.24-2.50
1 Week6.27   4.613.77
1 Month-16.21   -4.86-6.73
3 Months-21.43   -8.43-10.01
6 Months-24.92   -7.97-2.98
YTD-19.48   -6.17-10.69
1 Year-17.87   -5.461.51
3 Years Annualised-1.76   1.96-1.79
5 Years Annualised-2.68   -2.81-5.84
10 Years Annualised-0.17   -3.01-4.87
 
Category: Sector Equity Biotechnology
Category Index: Morningstar Gbl Biotechnology NR USD
Quarterly Returns (GBP)31/03/2025
 Quarter 1Quarter 2Quarter 3Quarter 4
2025-11.15---
20244.520.40-3.34-1.63
2023-7.083.04-1.3612.87
2022-15.31-1.8018.28-3.81
2021-4.390.871.70-6.54
2020-4.4226.440.241.64
 
 
 
Morningstar Rating™(Relative to Category)31/03/2025
 Morningstar ReturnMorningstar RiskMorningstar Rating™
3-YearAbove AverageAbove Average3 star
5-YearAverageAbove Average2 star
10-YearBelow AverageAverage2 star
OverallAverageAbove Average2 star
 
Category :  Sector Equity BiotechnologyClick here to see our Methodology
Volatility Measurements31/03/2025
 
3-Yr Std Dev21.34 %
3-Yr Mean Return4.07 %
 
3-Yr Sharpe Ratio0.00
 
Modern Portfolio Statistics31/03/202531/03/2025
 Standard IndexBest Fit Index
 Morningstar Gbl Biotechnology NR USD  Morningstar Gbl Biotechnology NR USD
3-Yr Beta0.910.91
3-Yr Alpha0.030.03
 
Investment Style Details31/03/2025
Morningstar Style Box®
Equity Style
SizeRel to Cat
Average Mkt Cap (Mil)USD 8070-
Market Capitalisation% of Equity
Giant5.22
Large16.14
Medium16.58
Small41.90
Micro20.16
Valuations and Growth RatesEquity PortfolioRelative to Category
Price/Prospective Earnings16.530.85
Price/Book3.560.96
Price/Sales5.611.16
Price/Cash Flow18.871.14
Dividend-Yield Factor0.320.91
 
Long-Term Projected Earnings Growth7.791.71
Historical Earnings Growth-14.832.36
Sales Growth14.814.65
Cash-Flow Growth-6.660.70
Book-Value Growth8.251.25
 
Category: Sector Equity Biotechnology
Asset Allocation31/03/2025
Asset Allocation
 % Long% Short% Net Assets
Stock98.050.0098.05
Bond0.170.000.17
Property0.000.000.00
Cash2.991.211.78
Other0.000.000.00
World Regions31/03/2025
 % of EquityRelative to Category
United States87.231.06
Canada1.791.60
Latin America0.000.00
United Kingdom1.410.39
Eurozone3.880.90
Europe - ex Euro0.550.10
Europe - Emerging0.00-
Africa0.00-
Middle East0.000.00
Japan0.000.00
Australasia0.000.00
Asia - Developed0.000.00
Asia - Emerging5.142.43
 
Category: Sector Equity Biotechnology
Sector Weightings31/03/2025
 % of EquityRelative to Category
HealthcareHealthcare100.001.02
 
Category: Sector Equity Biotechnology
Top 10 Holdings31/03/2025
 Portfolio NEW
Total Number of Equity Holdings62
Total Number of Bond Holdings0
Assets in Top 10 Holdings39.98
NameSectorCountry% of Assets
Gilead Sciences Inc206United States6.13
Insmed Inc206United States5.29
argenx SE ADR206China5.04
Amgen Inc206United States4.50
Regeneron Pharmaceuticals Inc206United States3.80
Alnylam Pharmaceuticals Inc206United States3.63
TG Therapeutics Inc206United States3.42
BridgeBio Pharma Inc206United States2.75
Blueprint Medicines Corp206United States2.72
Madrigal Pharmaceuticals Inc206United States2.68
 
Increase Decrease New since last portfolio
Category: Sector Equity Biotechnology
 
Management
Name of CompanyPictet Asset Management (Europe) SA
Phone+352 467 171-1
Websitewww.am.pictet
Address15, avenue J.F. Kennedy
 Luxembourg   L-1855
 Luxembourg
DomicileLuxembourg
Legal StructureSICAV
UCITSYes
Inception Date27/06/2000
Fund Advisor(s)
Pictet Asset Management SA
Fund ManagerTazio Storni
Manager Start Date26/05/2016
Fund ManagerMarco Minonne
Manager Start Date01/06/2020
Career Start Year2000
 
Biography
Marco Minonne, CFA, Senior Vice President, rejoined the firm in 2013. Marco is part of the Growth Equity Group which is responsible for Neuberger Berman’s Mid Cap Growth and Small Cap Growth strategies. He is an Associate Portfolio Manager on Small Cap Growth and a Research Analyst covering the health care sector on Mid Cap Growth. Prior to rejoining Neuberger Berman, Marco was a senior therapeutic analyst with Columbia Management. He has previously held research analyst positions at Citadel Investment Group, Neuberger Berman and Northern Trust Bank. Marco has extensive buy-side experience in health care and has been involved in both long-only and long-short strategies. Marco earned a Bachelor of Arts in Finance and Economics from the University of Iowa and has been awarded the Chartered Financial Analyst designation.
Fund ManagerLydia Haueter
Manager Start Date26/05/2016
Fund ManagerEugénio Martin-Fougeroux
Manager Start Date01/01/2023
Fees and Expenses
Sales Charges (Maximum) 
Max Initial Charge3.00%
Max Exit Charge*1.00%
Annual Charges
Max Annual Management Charge2.90%
Ongoing Charge2.70%
Purchase Details
Minimum Investments
Initial-
Additional-
Savings-
Tax Free Savings Schemes
ISAsYes